MARKET

CERS

CERS

Cerus
NASDAQ
1.290
-0.070
-5.15%
After Hours: 1.299 +0.009 +0.71% 19:46 05/09 EDT
OPEN
1.350
PREV CLOSE
1.360
HIGH
1.360
LOW
1.280
VOLUME
661.81K
TURNOVER
--
52 WEEK HIGH
2.540
52 WEEK LOW
1.120
MARKET CAP
246.60M
P/E (TTM)
-12.6595
1D
5D
1M
3M
1Y
5Y
1D
Analysts Offer Insights on Healthcare Companies: Cerus (CERS), Stryker (SYK) and Praxis Precision Medicines (PRAX)
TipRanks · 6d ago
Weekly Report: what happened at CERS last week (0428-0502)?
Weekly Report · 6d ago
BTIG Sticks to Its Hold Rating for Cerus (CERS)
TipRanks · 6d ago
Cerus Corporation Q1 2025 Earnings Call Highlights
TipRanks · 05/03 00:29
Analysts Are Bullish on These Healthcare Stocks: Cerus (CERS), Madrigal Pharmaceuticals (MDGL)
TipRanks · 05/02 12:40
Cerus Corporation Reports Strong Q1 2025 Revenue Growth
TipRanks · 05/02 04:18
Cerus Corp reports results for the quarter ended March 31 - Earnings Summary
Reuters · 05/02 03:34
Cerus targets $194M-$200M revenue in 2025 with double-digit growth and new product launches
Seeking Alpha · 05/02 00:27
More
About CERS
More
Cerus Corporation is a biomedical products company. The Company is focused on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System, which is based on its proprietary technology for controlling biological replication, is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. Its INTERCEPT Blood System is intended for use with blood components and certain of their derivatives: platelets, plasma, red blood cells and to produce INTERCEPT Fibrinogen Complex (IFC), and pathogen reduced plasma, cryoprecipitate reduced. The INTERCEPT Blood System for Cryoprecipitation uses its plasma system to produce IFC for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. In addition, the INTERCEPT Blood System for Cryoprecipitation is used to produce pathogen reduced plasma, cryoprecipitate reduced.
Recently
Symbol
Price
%Change

Webull offers Cerus Corp stock information, including NASDAQ: CERS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CERS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CERS stock methods without spending real money on the virtual paper trading platform.